Article Information
History
- March 9, 2022.
Article Versions
- Version 1 (June 21, 2021 - 05:15).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- B N Arch1,†,
- D Kovacs*,2,
- J T Scott*,3,
- A P Jones1,
- E M Harrison4,
- A Rosala-Hallas1,
- C G Gamble1,
- P J M Openshaw5,
- J K Baillie6,
- M G Semple7,8 and
- ISARIC4C Investigators
- 1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
- 2Institute of Biodiversity, Animal health and Comparative Medicine, University of Glasgow, Glasgow, UK
- 3MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
- 4Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK
- 5National Heart and Lung Institute, Imperial College London, London, UK
- 6Roslin Institute, University of Edinburgh, Edinburgh, UK
- 7Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
- 8Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK
- ↵†Corresponding Author:
B N Arch, Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK. barbara.arch{at}liverpool.ac.uk.
Posted March 09, 2022.
Evaluation of the effectiveness of remdesivir in severe COVID-19 using observational data from a prospective national cohort study
